Stockwinners Market Radar for April 18, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EDT Palo Alto Networks CEO sell $2.78M in common stock - In a regulatory filing, Palo Alto Networks disclosed that its CEO Nikesh Arora sold 13.8K shares of common stock on April 17th in a total transaction size of $2.78M.

20:28 EDT Cathie Wood's ARK Investment bought 211.3K shares of Roblox today

18:35 EDT Netflix says 'Love is Blind' live reunion show drew 6.5M viewers

18:30 EDT Netflix 'sorry' about live 'Love is Blind' show problems - Says film division "doing great." Says Netflix films that won awards and received critical acclaim also had high viewership numbers on the platforms. Says "sorry" about disappointing viewers during live "Love is Blind" show.

18:23 EDT Agnico Eagle Executive Chairman: We like our positioning - In an interview on CNBC's Mad Money, Sean Boyd said, "We've positioned the company to be the third largest gold producer. We think we're going to see higher gold prices." He noted there is significant M&A in the space because there aren't a lot of new gold mines. He doesn't think supply is going to increase as gold prices rise. The lead time from discovery to production is longer than ever, he added.

18:07 EDT Intuitive Machines and KBR joint venture awarded contract by NASA - Intuitive Machines (LUNR) announced NASA awarded Space & Technology Solutions, the DBA for Space Networks Solutions, a joint venture led by Intuitive Machines with KBR (KBR), a cost-plus-fixed-fee indefinite-delivery, indefinite-quantity contract meant to support work related to the Joint Polar Satellite System, NASA's Exploration and In-space Services. The single-award contract has a five-year base performance period and a maximum ordering value of $719M. The NASA OMES III contract's principal purpose is to support the NASA GSFC Engineering and Technology Directorate, or ETD. ETD is an end-to-end science mission operation that is instrumental in designing missions, building satellites and instruments, operating, and controlling spacecraft, and acquiring and distributing data to the worldwide science community.

17:52 EDT Shares of Marten Transport fall over 6% after Q1 revenue misses estimates - Shares of temperature-sensitive truckload carrier Marten Transport (MRTN) are dropping over 6% in after-hours trading on Tuesday evening after reporting revenue of $298M for the first quarter from $287.3M for the first quarter of 2022. Analysts were expecting revenue 309.89M. The company beat analyst estimates by a penny on the bottom line with 28c against 27c consensus estimates. Executive Chairman Randolph L. Marten stated, "Our bright and determined people executing our unique business model produced solid operating results despite the impact of widespread severe winter weather and a freight market which has considerably softened from the exceptionally tight conditions during the first half of last year. The market has become unsustainable for the smaller carriers who comprise a significant portion of total capacity, and who are expected to continue the recent increased industry exit rate." "We believe that we are well-positioned to capitalize on profitable organic growth opportunities across our five distinct but complementary business platforms with our emphasis on premium service, data-driven operating efficiencies and cost controls - and, as a result, to expand the total capacity we provide transporting and distributing the essential food, beverages and other consumer goods to support at a fair price our diverse and growing customer base." Other publicly traded companies in the space include: Landstar System (LSTR), J.B. Hunt Transport (JBHT), Old Dominion Freight Line (ODFL),Knight-Swift Transportation (KNX) , and Covenant Logistics Group (CVLG).

17:12 EDT Fulton Financial slips 4% to $12.60 after Q1 earnings miss

17:08 EDT AES Corp. announces pact to terminate PPA for coal-fired plant in Maryland - The AES Corporation announced an agreement to terminate the Power Purchase Agreement for its 205 MW Warrior Run coal-fired power plant in Maryland. The offtaker, Potomac Edison, a subsidiary of FirstEnergy Corp., agreed to terminate the PPA for a total consideration of $357M, subject to approval by the Maryland Public Service Commission. If approved, the early termination of the PPA is forecasted to save Potomac Edison's customers nearly $80M over the next seven years, and will help the State of Maryland achieve its decarbonization targets. "This agreement is another milestone in our journey toward decarbonization," said Andres Gluski, AES President and Chief Executive Officer. "Following the contract termination, we see interesting opportunities to repurpose the Warrior Run site for low carbon solutions that continue to serve local communities." Under the terms of the agreement, AES will continue to operate the Warrior Run plant through at least May 2024. AES will work with existing employees to manage a responsible transition. AES will maintain full operational control of the site following decommissioning.

17:06 EDT Camber Energy discloses communication from NYSE American - Camber Energy announced that on April 12, 2023 it received a letter from the NYSE American LLC advising the company is not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide given the reported stockholders' deficit as of December 31, 2022, and losses from continuing operations and/or net losses in its five most recent fiscal years then ended. The Notice has no immediate impact on the listing of the Company's shares of common stock, par value $0.001 per share, which will continue to be listed and traded on the NYSE American during the period mentioned below, subject to the Company's compliance with the other listing requirements of the NYSE American. The Common Stock will continue to trade under the symbol "CEI", but will have an added designation of ".BC" to indicate the status of the Common Stock as "below compliance". The notice does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission

17:04 EDT Intuitive Surgical raises FY23 procedure growth to up 18%-21% from 12%-16% - Sees FY23 gross profit margin 68%-69%. Sees FY23 operating expense growth 11%-15%.Sees FY23 tax rate 22%-24%. Says core business remains strong. Says saw surprising procedure strength in the quarter. Says U.S. performance was above trend. Says hospitals working through staffing restraints. Says expects to launch Ion in the UK as first entry into Europe. Says focused on increased adoption for procedures. Says pursuing expanded indications for new platforms. Says January and February were particularly strong. Says expects customers to be cautious in overall capital spending. Says operating expenses were moderately above expectations. Comments taken from Q1 earnings conference call.

16:49 EDT RE/MAX Holdings reports March home inventory was 56.4% higher year over year - March home sales jumped 37.7% over February, signaling the start of the peak spring and summer seasons in the report's 52 metro areas. While inventory was down 2.8% from February's total, March inventory was 56.4% higher year over year - due in part to the combination of pending sales and closings being down, leaving homes on the market longer than they were a year ago. The median sales price of $396,000 in March was down 2.0% year over year." Compared to last year, there's a lot to like about this housing market, including lower prices and less competition for available listings. Although it would be good to see more new listings coming onto the market, the current conditions offer potential for home buyers and sellers alike," says RE/MAX President and CEO Nick Bailey. "For those interested in selling, demand for properties remains high and for buyers entering the market, this spring can be a prime time to make a move."

16:46 EDT Western Alliance jumps 15% to $37.59 after Q1 results beat estimates

16:35 EDT Western Alliance reports Q1 net interest margin 3.79% vs. 3.32% last year - Reports Q1 ROE 1.43% vs. 1.64% last year and CET1 ratio of 9.4% vs. 9.0% last year.

16:32 EDT Li-Cycle restates financial statements for FY22 - The company states: "The Company determined that unrealized fair value gains on financial instruments resulting from fair value revaluations of the conversion feature of the Company's convertible debt and warrants were understated by $18.2 million for the two months ended December 31, 2021. As a result, corresponding adjustments have been made to the Statements of income and comprehensive income and Statements of cash flows for the two months ended December 31, 2021 and corresponding notes. These adjustments result in an increase of $18.2 million in Other income, Net income before taxes, Net income attributable to shareholders of Li-Cycle, and Net income and comprehensive income; an increase in Earnings per common share of $0.12; and an increase in Earnings per common share of $0.11, for the two months ended December 31, 2021. The results pertaining to the two months ending December 31, 2022 are unchanged."

16:31 EDT WeWork discloses continued listing notice from NYSE - WeWork "announced that on April 12, 2023, it received a notice from the New York Stock Exchange notifying the Company that it is not in compliance with the NYSE's continued listing standards because as of April 11, 2023, the average closing price of the Company's Class A Common Stock was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company's Common Stock from the NYSE. The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the deficiency. Pursuant to the NYSE's rules, the Company has a six-month period following receipt of the Notice to regain compliance with the NYSE's minimum share price requirement."

16:25 EDT CDW falls 8% after negative Q1 revenue pre-announcement - Shares of CDW are down 8% or $15.29 afterhours at $175.00 after the company guided Q1 revenue below consensus and also forecast FY23 to be modestly below $9.79 reported in FY22 against consensus of $10.39.

16:19 EDT M3-Brigade approves extension period for business combination - M3-Brigade Acquisition III announced that, upon the request of the Company's sponsor, M3-Brigade Sponsor III LP, its board of directors has approved an extension of the period of time the Company has to consummate its initial business combination by three months, from the current deadline of April 26 until July 26, pursuant to the Company's amended and restated certificate of incorporation. In connection with the Extension, the Sponsor, or its affiliates or designees will deposit an additional $1,696,500 into the Company's trust account, in part from the Company's working capital, for the benefit of the Company's public stockholders. The Company's stockholders are not entitled to vote on or redeem their shares in connection with the Extension. The Sponsor has informed MBSC that it intends to request additional extensions of the period of time the Company has to consummate its initial business combination, to the extent necessary to complete its previously announced business combination with Greenfire Resources. The Charter permits a total of four three-month extensions, of which this is the third.

16:16 EDT Senseonics announces first pediatric study participant in ENHANCE trial - Senseonics Holdings "announced the first pediatric study participant has been inserted with Eversense(R) 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes and obesity, under the direction of Dr. Timothy Bailey. The ENHANCE Trial is designed to evaluate the accuracy and safety of the Eversense system for up to one year. Over 165 adult subjects were inserted with Eversense systems in four centers across the United States. Enrollment for the 365-day sensor configuration was completed in September 2022 and the last patient is expected to complete their 365-day visit during the third quarter of 2023. Data gathered in this trial is also planned to be used to submit for the integrated continuous glucose monitoring, iCGM, designation in 2023. An investigational device exemption supplement was submitted and approved for expansion of the trial to allow for pediatric patients 14 to 18 years of age and the first pediatric study participants were enrolled in Q2 2023."

16:14 EDT ClearPoint Neuro with teams with NE Scientific on software solution - ClearPoint Neuro announced an exclusive worldwide agreement with NE Scientific a leader in biophysics simulation, to develop a GPU-accelerated software solution for modeling of drug infusions delivered with the ClearPoint SmartFlow cannula. Under the terms of the agreement, this first of many software collaborations will enable simulation of patient-specific infusion in real time to predict the distribution of therapeutic agents in 4D before the actual procedure. Coupled with Maestro, this new software will allow optimization of infusion parameters including target points, flow rate, infusion coverage and leakage outside of target-specific boundaries. The simulation software will require standard structural and diffusion pre-operative MRI scans. Infusions can be planned either in the pre-operative MRI space and registered to intra-operative MRI case data, or in the OR space using an intra-operative CT. "The accuracy of the ClearPoint system allows for precise dosing and targeted delivery of therapeutic agents across the blood brain barrier. Real time simulation of patient-specific infusion would be of tremendous help to neurosurgeons performing these procedures. It presents a unique opportunity for optimization and monitoring of infusion parameters, including cannula tip location, flow rate, and percentage coverage," commented Lyubomir Zagorchev, Vice President, Clinical Science and Applications at ClearPoint Neuro. "Accurate patient-specific quantification and visualization of infusion coverage has the potential to change the current practice of setting up fixed clinical protocols for pharma trials. The dose of delivered therapeutic can be visualized and quantified during a procedure based on patient-specific data. That will reduce variability that may lead to sub-optimal delivery, and even failed clinical trials."

16:13 EDT United Airlines sees FY23 CapEx about $8.5B

16:11 EDT Adeia announces Christina Sawyer as chief people officer - Adeia announced that Christina Sawyer joined Adeia (ADEA) as the company's chief people officer on Monday, April 17. Sawyer joins Adeia from Electronic Arts (EA), where she was most recently vice president of integrated operations.

16:09 EDT Finch enters CP101 clinical trial agreement with Brigham and Women's Hospital - Finch Therapeutics announced that it has entered into a clinical trial agreement with Brigham and Women's Hospital for the evaluation of CP101 in ulcerative colitis. The company also announced updates to its license agreement with the University of Minnesota. Under the clinical trial agreement, Brigham and Women's Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101 in patients with mild-to-moderate ulcerative colitis. The study is designed to generate data on safety, pharmacokinetics, pharmacodynamics and clinical efficacy, and aims to build on a growing body of evidence supporting the role of the microbiome in improving outcomes for patients suffering from ulcerative colitis. Topline data from this clinical study is anticipated in 2025. The company also announced that it has amended its license agreement with the University of Minnesota, through which Finch has exclusively licensed 13 issued patents and 7 patent applications covering specific approaches to formulations comprising human fecal microbes, methods of increasing microbiota diversity, and methods of decreasing the relative abundance of certain bacteria. A key feature of the amendment allows Finch to satisfy certain performance milestones through sublicensing agreements, aligning with Finch's new strategic focus on collaborations and partnerships.

16:07 EDT Calyxt announces effectiveness of registration statement on Form S-4 - Calyxt and Cibus announced that the registration statement on Form S-4, initially filed with the U.S. SEC by Calyxt on February 14, and amended on April 14, has been declared effective by the SEC. The proxy statement/prospectus contains important information about the proposed merger transactions, the merger agreement and the proposals to be considered at the Special Meeting. The combined company is expected to be renamed Cibus, Inc. and remain listed on the Nasdaq Capital Market under the proposed ticker symbol CBUS.

16:07 EDT Netflix down 9% following quarterly report - Netflix shares are down $28.81, or nearly 9%, to $304.89 in after-hours trading.

16:04 EDT Aerojet Rocketdyne delivers propulsion for Artemis III mission - Aerojet Rocketdyne recently completed the four RS-25 engines that will power the core stage of NASA's super heavy-lift Space Launch System SLS rocket during the historic Artemis III mission. Slated for launch around the middle of the decade, Artemis III is a planned lunar landing mission that will return humans to the surface of the Moon for the first time in more than 50 years. "The Artemis III mission is pivotal in our nation's goal to return American astronauts to the surface of the Moon, establish a sustained presence there and pave the way for crewed missions to Mars," said Eileen P. Drake, Aerojet Rocketdyne CEO and president. "As our nation makes this next giant leap in its space program, it is leveraging the extensive knowledge and lessons learned that were gained during our earlier exploration efforts, including the Apollo, Space Shuttle and Artemis I missions. We are truly standing on the shoulders of those who pioneered the exploration of deep space." The four RS-25 engines that will power the SLS rocket's core stage during the Artemis III mission have been upgraded following their service during the shuttle program and will now generate about 2 million pounds of combined thrust. The Artemis III RS-25 engines safely flew 138 individual astronauts to orbit and supported 26 Space Shuttle missions.

16:04 EDT United Airlines reduced adjusted total debt by $4.6B in the last 12 months

16:03 EDT Hancock Whitney reports Q2 deposits $29.6B, up 2% from Q4 - Q1 average deposits were $28.8B, "virtually unchanged linked-quarter".

16:02 EDT Netflix reports Q1 global streaming paid net additions of 1.75M - Netflix said in its quarterly letter to investors: "Paid net adds amounted to 1.8M for Q1 vs. -0.2M in the year ago quarter."

15:35 EDT Netflix to wind down DVD.com later this year - Netflix Co-CEO Ted Sarandos stated in a post to the company's newsroom: "After an incredible 25 year run, we've decided to wind down DVD.com later this year. Our goal has always been to provide the best service for our members but as the business continues to shrink that's going to become increasingly difficult. So we want to go out on a high, and will be shipping our final discs on September 29, 2023. Those iconic red envelopes changed the way people watched shows and movies at home - and they paved the way for the shift to streaming... We feel so privileged to have been able to share movie nights with our DVD members for so long, so proud of what our employees achieved and excited to continue pleasing entertainment fans for many more decades to come." Reference Link

14:44 EDT SEI Investments increases stock repurchase program by $250M - The board of directors of SEI Investments approved an increase in its stock repurchase program by an additional $250M, increasing the available authorization under the program to approximately $263M, the company announced.

14:34 EDT SAB Biotherapeutics spikes 33% after FDA grants BTD to SAB-176 - Shares of SAB Biotherapeutics are up 33% or 25c per share to $1.02 in late afternoon trading on Tuesday after the immunotherapies biopharma announced that the U.S. Food and Drug Administration, FDA, had granted Breakthrough Therapy Designation, BTD, to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.

13:48 EDT RYAH Group enters Master Distribution Agreement with OMNI - RYAH GROUP and OMNI Medical Services have signed a Master Distribution Agreement, whereby OMNI will supply RYAH's solutions for use in US clinical trials and research studies of medical cannabis. OMNI Medical Services has signed a non-exclusive master distribution agreement, enabling OMNI to market and sell the RYAH Group's products in support of clinical research trials and studies throughout the United States. RYAH and OMNI would also like to update regarding an October 26, 2021 announcement of a non-binding letter of intent for RYAH to acquire 100% of the business and assets of Omni. Both parties agree that the potential acquisition is not of interest at this time, whereas the business synergies and collaboration potential continue to be of significant interest. RYAH would also like to update that it has received a second comment letter from the Ontario Securities Commission regarding the Failure-to-File Cease Trade Order issued under National Policy 11-207. The OSC have requested further clarifications on documents submitted to date, which RYAH management is working to address, hoping to obtain the revocation of the FFCTO as soon as possible. RYAH will keep investors updated with regular news releases

13:37 EDT Moleculin Biotech reports preclinical data on Annamycin - Moleculin Biotech announced that "positive" preclinical data regarding the company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research, or AACR, Annual Meeting 2023. ANN exhibited significantly higher accumulation in the liver parenchyma when compared to DOX, or 6-fold higher AUC values, the company reported. "Researchers observed clear inhibition of the subcutaneous tumor growth after systemic administration of L-ANN," the company stated. "Annamycin has continued to demonstrate in preclinical models promising results in hard-to-treat tumors. We are pleased with the findings from these preclinical models in HCC, the most common type of primary liver cancer that is responsible for more than 12,000 deaths per year in the US. The high antitumor activity seen preclinically with Annamycin is very encouraging and provides validation for expanded studies to assess activity in different tumor liver metastasis models as well as HCC models," commented Walter Klemp, Chairman and CEO of Moleculin.

13:34 EDT Karyopharm announces updated results from Phase 1 study of Selinexor - Karyopharm Therapeutics announced updated results from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naive myelofibrosis. The data, featured in a poster presentation at the American Association for Cancer Research, or AACR, Annual Meeting 2023, "show that rapid, deep and sustained spleen responses and robust symptom improvement were achieved at both weeks 12 and 24, in patients treated with selinexor 60mg in combination with ruxolitinib," the company said. As of the February 24, 2023 data cut-off date, 24 patients had been assigned to either a 40mg or 60mg once weekly dose of selinexor, combined with ruxolitinib. All patients initiated treatment greater than 24 weeks prior to the data cut-off date. Both the efficacy and safety data support the 60 mg dose of selinexor as the recommended dose in combination with ruxolitinib. A double-blind, randomized, Phase 3 trial of selinexor 60 mg in combination with ruxolitinib versus placebo in combination with ruxolitinib in JAKi treatment-naive patients with myelofibrosis is expected to initiate in the first half of 2023. "We are enthusiastic about the impressive spleen volume reductions and robust symptom improvement observed with the 60mg dose of selinexor and ruxolitinib combination at week 24, which represent very meaningful improvements relative to the current standard of care of ruxolitinib alone. These data suggest that the combination of selinexor and ruxolitinib has the potential to be a transformative therapy for first line myelofibrosis patients. We are also very encouraged by the preliminary data showing rapid normalization in platelets and stability of hemoglobin levels, as potential evidence of disease modification for these patients. We look forward to building upon these findings as we plan the initiation of a pivotal Phase 3 study in front-line myelofibrosis later this quarter," said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm.

13:15 EDT Unique Fabricating trading resumes

12:25 EDT Unique Fabricating trading halted, news pending

12:00 EDT Altus Power falls -6.5% - Altus Power is down -6.5%, or -33c to $4.69.

12:00 EDT San Juan Basin Royalty Trust falls -8.8% - San Juan Basin Royalty Trust is down -8.8%, or -91c to $9.46.

12:00 EDT Sibanye Stillwater rises 10.2% - Sibanye Stillwater is up 10.2%, or 88c to $9.48.

11:35 EDT Southwest resumes operations, says pause due to 'firewall failure' - Southwest issued a statement to media after its pause in flights earlier this morning, stating: "Southwest has resumed operations after temporarily pausing flight activity this morning to work through data connection issues resulting from a firewall failure. Early this morning, a vendor-supplied firewall went down and connection to some operational data was unexpectedly lost. Southwest Teams worked quickly to minimize flight disruptions. We ask that travelers use Southwest.com to check flight status or visit a Southwest Airlines Customer Service Agent at the airport for assistance with travel needs. We appreciate the patience of our Customers and Employees during this morning's brief disruption."

11:28 EDT Boeing doesn't see 737 issue changing long-term guidance, says CEO - CEO Dave Calhoun says Boeing hasn't altered its 737 supplier master schedule, including planned rate increases for the 737 MAX, because of the new issue. Comments taken from Boeing's Annual Shareholder meeting.

11:23 EDT Sega to acquire Rovio Entertainment in EUR706M deal - Sega Sammy said it resolved to implement a tender offer to acquire Rovio Entertainment Oyj, a mobile game company headquartered in Finland, through Sega's wholly-owned UK subsidiary Sega Europe Limited and Sega Sammy Holdings has entered into a definitive agreement with Rovio pursuant to which the Tender Offer is made. Through the Tender Offer, Sega aims to acquire the entirety of Rovio's outstanding shares and options at EUR 9.25 per share and EUR 1.48 per option, or EUR 706M in total. The acquisition is a friendly takeover, as Rovio's board of directors has agreed to, and has expressed support towards the Tender Offer. Shareholders in Rovio who in aggregate hold shares corresponding to approximately 49.1% of the outstanding shares and votes in Rovio, have irrevocably undertaken to accept the offer, subject to certain customary conditions. The acquisition is expected to close in the second quarter of FY2024/3 and is contingent on the completion of reviews under applicable antitrust laws and other customary conditions. "Among the rapidly growing global gaming market, the mobile gaming market has especially high potential, and it has been SEGA's long-term goal to accelerate its expansion in this field," said Sega Sammy president and group CEO Haruki Satomi. "I feel blessed to be able to announce such a transaction with Rovio, a company that owns "Angry Birds", which is loved across the world, and home to many skilled employees that support the company's industry leading mobile game development and operating capabilities. Historically, as represented by the "Sonic the Hedgehog" series, SEGA has released countless video game titles to various gaming platforms. I am confident that, through combination of both companies' brands, characters, fanbase, as well as corporate culture and functionality, there will be significant synergies created going forward."

11:14 EDT Lockheed Martin remains on track to meet financial expectations for full year - Says had a 'solid start' to the year. Says anticipates heightened emphasis on national security. Says remains fully committed to developing hypersonic technology. Says demand for high-performing systems in RMS continues to be strong. Says continues to grow 'significant' partnership with Australia. Comments taken from Q1 conference call.

10:48 EDT Southwest confirms ground stop implemented due to 'intermittent issues' - Southwest Airlines stated in a reply to a tweet from a customer: "We have had to implement a ground stop as a result of intermittent issues that were experienced, and we should hopefully be resuming our operation as soon as possible. I apologize for any inconvenience this may cause, but we'll be here for you if you need any assistance." Reference Link

10:41 EDT FAA says Southwest requested 'pause' of airline's departures - The official twitter account of the Federal Aviation Administration tweeted: "Southwest Airlines requested the FAA pause the airline's departures. Please contact Southwest Airlines for more." Southwest Airlines has been responding to tweets from its own customer service accounts and referring to "intermittent technology issues." Reference Link

10:25 EDT GXO Logistics expands partnership with Vivienne Westwood - GXO Logistics is extending and expanding its partnership with international fashion and luxury goods company Vivienne Westwood in a 9,500-square-meter solution at its shared services site in Carisio, Italy. GXO's support for Vivienne Westwood includes value-added services such as reconditioning, quality control, labelling, packing, gift boxing and re-labeling.

10:05 EDT AirSculpt slips as Storm King says financial prospects 'decidedly ugly' - In a recently published short report, Storm King Reports says that an "investigation reveals another side to AirSculpt's business equation that doesn't make it into these photo galleries. For a significant population of AirSculpt's clients, its claims of pain-free body transformation do not hold up... Patient dissatisfaction is hardly the company's only problem." Further, Storm King claims that "AirSculpt's own financial prospects are decidedly ugly. And while its income statement is splattered with red ink, the company has much bigger problems than profitability on its immediate horizon. That's because a small group of insiders, according to company filings, were able to execute a series of transactions that provided them over 95 percent of the money the company raised just before and after its initial public offering. AirSculpt's financial flexibility has been greatly reduced." Shares of AirSculpt have dropped about 2% to $4.95 in Tuesday morning trading. Reference Link

10:00 EDT Douglas Dynamics falls -5.2% - Douglas Dynamics is down -5.2%, or -$1.54 to $28.29.

10:00 EDT iHuman falls -8.8% - iHuman is down -8.8%, or -30c to $3.09.

10:00 EDT Itau Corpbanca rises 5.8% - Itau Corpbanca is up 5.8%, or 20c to $3.59.

09:52 EDT Goldman Sachs sees pace of fundraising slowing for rest of year

09:47 EDT Clevon chooses T-Mobile as preferred connectivity provider for robot fleet - Clevon named T-Mobile as the preferred connectivity provider for its fleet of Autonomous Robot Carrier in the United States. Under the long-term deal, T-Mobile will provide IoT solutions for Clevon's latest ARC - the all-electric, multifunctional CLEVON 1. Clevon will rely on T-Mobile's award-winning network and IoT solutions to help power reliable, safe and efficient fleet operations for on-demand driverless delivery services.

09:47 EDT Algonquin Power falls -4.8% - Algonquin Power is down -4.8%, or -41c to $8.09.

09:47 EDT Itau Corpbanca rises 5.5% - Itau Corpbanca is up 5.5%, or 19c to $3.58.

09:47 EDT Sibanye Stillwater rises 8.5% - Sibanye Stillwater is up 8.5%, or 73c to $9.34.

09:45 EDT Nascent Biotech submits Phase 2 clinical research protocol to FDA - Nascent Biotech announced that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the next phase in the development of Pritumumab. Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA. The Company anticipates initial comments from the FDA approximately 30 days from the date of filing.

09:43 EDT CMC Metals announces drill results at Silver Hart, Yukon - CMC Metals announces results from its drill program conducted at its flagship Silver Hart Project in the 2022 exploration season. Approximately 4,404 meters of diamond drilling was completed in 25 holes. Highlights include; Hole SHM22_06 intersected 813 g/t AgEq over 8.25 meters, including a 0.60 meter intersection of 2,827 g/t silver, 18.7% zinc, and 1.6% lead. The drill program tested five areas of the property including; An extension of the KL vein - Main Zone; An area of the carbonate belt proximal to the Main Zone veins; The St. Patrick Vein; T1 Conductor; and The T4 Conductor.John Bossio, Chair noted, "It is evident that mineralization at Silver Hart is not limited to the vein system and the potential to find significant skarn-related and/or carbonate replacement style deposits still exists. The Board feels it is now important to conduct a review of over 15 years of exploration at Silver Hart in order to gain a better understanding of the mineralizing system that will aid in pinpointing new targets outside of the vein systems."

09:40 EDT Relay Therapeutics trading halted, news pending

09:38 EDT Goldman Sachs 'well prepared' if environment weakens further, says CEO

09:35 EDT Windtree Therapeutics Inc trading resumes

09:31 EDT Adagene presents clinical data for anti-CTLA-4 SAFEbody ADG126 - Adagene announced interim results from its combination dose escalation studies of the masked, anti-CTLA-4 SAFEbody, ADG126, presented at the AACR Annual Meeting in Orlando, Florida, April 14-19, 2023. Two poster presentations on ADG126 SAFEbody reported results of ongoing phase 1b/2 trials at multiple dosing regimens in combination with either pembrolizumab or toripalimab, as well as updated data for ADG126 monotherapy in heavily pre-treated patients. Key findings include: Best-in-class Safety Profile Reinforced in Combination with Anti-PD-1: In dose escalation studies of ADG126 in combination with anti-PD-1 treatments, ADG126 continues to demonstrate a best-in-class safety profile at doses from 6 mg/kg up to 10 mg/kg. The combination was well tolerated with no dose-limiting toxicities observed with repeat cycles, including in patients who received four or more cycles in the combination cohort with toripalimab. Confirmed Clinical Responses & Tumor Shrinkage in Combination with Anti-PD-1: In the heavily pre-treated patient groups, clinical responses and tumor shrinkage were observed during combination dose escalation. Compelling Monotherapy Safety Profile with Prolonged Stable Disease Supports ADG126 Mechanism: An additional cohort of 30 patients who received ADG126 monotherapy showed a compelling safety profile for ADG126, with no Grade 3 or higher TRAEs reported at repeat doses up to 20 mg/kg. Across all dose levels, the disease control rate was 37% among 27 evaluable patients. Prolonged stable disease was observed in five patients, with notable tumor shrinkage observed in an ovarian cancer patient who received 25 cycles at 1 mg/kg and a non-small cell lung cancer patient who received 14 cycles at 20 mg/kg. Analysis of a clinical sample from a hepatocellular carcinoma patient previously treated with atezolizumab and bevacizumab demonstrated Treg depletion, supporting the mechanism of action for ADG126. Combination Dose Expansion Ongoing in MSS CRC: Dose expansion cohorts are currently underway evaluating ADG126 in combination with anti-PD-1 therapy with an update planned later in 2023. The cohorts evaluate disease control rate, progression free survival, overall survival and objective response rate. Multiple dosing schedules are being evaluated, including ADG126 10 mg/kg every three and six weeks.

09:28 EDT Edible Garden provides update on ongoing initiatives - Edible Garden AG provided an update on ongoing initiatives the Company has taken to establish its leadership and reinforce its commitment to food safety. Jim Kras, Chief Executive Officer of Edible Garden, commented, "Consumers demand food that is not only nutritious and sustainably produced but, most importantly, safe to consume. Recent produce recalls have only reinforced these concerns. While no company is immune to potential risks, Edible Garden has consistently positioned itself at the forefront of the industry. Embodying our 'Simply Local...Simply Fresh' mission, we pledge to deliver products cultivated using the safest standards and most energy-efficient technologies available. We uphold protocols throughout the growing, harvesting, and packaging processes within our clean, controlled, indoor environment to ensure our produce consistently meets standards. In line with this commitment, Edible Garden actively engages with The Global Food Safety Initiative, an industry-driven initiative providing thought leadership and guidance on essential food safety management systems to maintain safety across the supply chain. This cooperative effort brings together the world's leading food safety experts from diverse sectors, including retail, manufacturing, food service, international organizations, governments, academia, and service providers catering to the global food industry."

09:27 EDT Immuneering down 5% at $11.53 after pricing $30M stock offering

09:25 EDT P.F. Chang to transform digital presence with Progress Sitefinity - Progress announced that P.F. Chang's has transformed its digital presence with Progress Sitefinity, dramatically improving site speed and providing exceptional usability for its customers. The company said, "As the digital world continues to evolve, P.F. Chang's saw an opportunity to upgrade its website design and supporting technologies and ensure its digital presence supports the needs of the modern consumer. Additionally, P.F. Chang's is deeply committed to providing exceptional usability, with strict adherence to Web Content Accessibility Guidelines Level AA and accommodating users of all types as consistent with the American Disabilities Act."

09:24 EDT Iveda Solutions partners with Evergreen Aviation - Iveda announces a partnership with aircraft maintenance solutions provider, Evergreen Aviation Technologies to bring cutting-edge Unmanned Aerial Vehicles to the global market. Through this collaboration, Iveda will also gain worldwide rights to promote and sell military grade drones that can fly at 10,000 to 30,000 feet, vastly expanding EGAT's reach cross-border. Leveraging each company's technological developments, Iveda and EGAT together will provide governments and military groups around the world access to state-of-the-art smart drones, effectively enhancing surveillance capabilities. Through this joint operation, EGAT will provide Iveda with the assets, technical support, and training to facilitate the promotion and sale of its UAV products on a global scale, especially important as Fortune Business Insights predicts the UAV drone market to reach $25.13B by 2027. Together, EGAT and Iveda will explore the development of smart drone features, including Iveda's AI Video Analytic and sensor technologies. Powered by AI technology, smart drones can send real-time alerts and detections to those monitoring for risks -- not just after the fact analysis. IvedaAI allows in-the-moment detection, allowing government and military officials to greatly speed up response times. Iveda-powered UAVs can monitor an expansive stretch of land in real time, making them critical, next-generation tools for military groups including coast guards. Providing visibility far beyond human sight, smart drones have the potential to prevent major security breaches, arming military and government associations around the globe with the technology needed to keep citizens safe.

09:21 EDT Joann CFO buys $44K in common stock - In a regulatory filing, Joann disclosed that its CFO Scott Sekella bought 27.7K shares of common stock on April 14th in a total transaction size of $44K. Shares of Joann are up about 4% in pre-market trading at $1.62.

09:20 EDT Tenable Holdings announces enhancements to Technology Ecosystem Program - Tenable announced significant enhancements to its Technology Ecosystem Program, driven by a shift toward exposure management solutions. The program has also expanded to include integrations with its innovative operational technology security solution, Tenable OT Security.

09:19 EDT Pressure BioSciences, Artisan Industries enter strategic agreement - Pressure BioSciences and Artisan Industries announced a strategic agreement between the companies. The agreement focuses on two highly important areas: PBIO will rent space and ancillary support in Artisan's state-of-the-art facilities, which will dramatically increase PBIO's manufacturing capacity for servicing the needs of its growing portfolio of Ultra Shear Technology-based nanoemulsion clients; and the relationship is expected to facilitate discussions between the companies towards an agreement that would secure Artisan as the exclusive manufacturer of PBIO's revolutionary UltraShear equipment. PBIO will continue to accept contracts for toll processing of customer's nanoemulsions requirements for the foreseeable future. Beginning in 2024, PBI's business plan will add a lease and license model, whereby the Company will be placing UltraShear equipment in the hands of customers at the cost of a monthly lease payment plus a toll/royalty rate on the output of the UST equipment. Under this growth strategy, the Company believes it may need hundreds or thousands of instruments over the coming years. The UST System contains a number of unique and complex designs and components; Artisan has an impressive history of innovation, professional manufacturing, and quality management - making them a natural and ideal choice for a prospective equipment building contract.

09:17 EDT Mangoceuticals debut commercial surpasses 5M views on YouTube - Mangoceuticals is pleased to announce that its commercial, which originally debuted on YouTube in November 2022, has surpassed over 5 million views.

09:16 EDT Fat Brands announces Johnny Rockets at Kempegowda International Airport - FAT Brands announces a new location in India at the Kempegowda International Airport in partnership with HMSHost. Located in Bengaluru, the capital city of Karnataka, the new Johnny Rockets serves the classic fare that put the brand on the map over 35 years ago, including juicy, made-to-order burgers and hand-spun shakes.

09:14 EDT Y-mAbs Therapeutics announces presentation of naxitamab data at AACR - Y-mAbs Therapeutics announced that a poster presentation featuring preclinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody will be presented at the AACR Annual Meeting 2023, which takes place in Orlando, Florida from April 14-19, 2023. The poster, "Investigational novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells," will be presented on April 18, 2023, from 1:30 to 5:00 pm EST. The disialoganglioside GD2 has been shown to be upregulated in triple-negative breast cancer and its high expression is associated with a poor prognosis. Furthermore, breast cancer stem-like cells are reported to be a major contributing factor for metastatic spread of TNBC and contribute to chemotherapy resistance, making them an important target for therapeutic intervention. Currently, there are no available therapeutic tools for targeting BCSCs. New preclinical data from M.D. Anderson Cancer Center demonstrate that TNBC with high GD2 expression inhibits immune cell infiltration and that naxitamab targets GD2+ BCSCs and may be able to inhibit the growth of BCSCs by enhancing macrophage-mediated phagocytosis, NK cell-mediated ADCC, and T cell-mediated cytotoxicity.

09:12 EDT Definitive Healthcare brings healthcare intelligence to Snowflake Marketplace - Definitive Healthcare (DH) announced the launch of its Atlas Dataset on Snowflake Marketplace (SNOW). Joint customers can now access and connect Definitive Healthcare's Atlas Dataset, enabling them to make better, more informed decisions about their commercialization efforts. "We're excited to bring our Atlas Dataset to the Snowflake Data Cloud," said Robert Musslewhite, CEO of Definitive Healthcare. "Now, joint customers of Definitive Healthcare and Snowflake can seamlessly integrate large amounts of our proprietary healthcare commercial intelligence into their existing workflow to better understand, compete, and win in the complex healthcare market."

09:11 EDT Definitive Healthcare announces DefinitiveConnect on Salesforce AppExchange - Definitive Healthcare announced it has launched DefinitiveConnect on Salesforce AppExchange, empowering customers to save time, build new opportunities, and drive revenue with Definitive Healthcare's commercial intelligence directly in Salesforce. DefinitiveConnect enables users to integrate key healthcare insights directly with Salesforce. With DefinitiveConnect, customers can import more than 300 data elements directly into an Account, Contact, or Lead record in Salesforce so customers can quickly access meaningful intelligence around facility metrics, key executives, and organizational news all in one place. "DefinitiveConnect helps our customers seamlessly access Definitive Healthcare data directly in Salesforce, without leaving their existing workflow," said Robert Musslewhite, CEO of Definitive Healthcare. "The combination of our healthcare commercial intelligence with Salesforce helps our joint customers make more informed and data-driven decisions around their commercial strategy and execution."

09:10 EDT Johnson & Johnson does not see material sales of Covid-19 vaccine after Q1 - Feels "very good" about product pipeline. Says remains "vigilant" regarding M&A, but will not due anything "out of desperation."

09:10 EDT DTE Energy announces commissioning of Meridian Wind - DTE Energy announced that Michigan's largest wind park, Meridian Wind, is now operational. Spanning three townships across Midland and Saginaw counties, the 225-megawatt wind park has 77 wind turbines and generates enough clean energy to power more than 78,000 homes. DTE managed all aspects of the Park's development, from land acquisition and permitting through construction, and will assume responsibility for the project's ongoing operations and maintenance. Meridian Wind Park is DTE's first self-developed renewable energy project since the development of Pinnebog Wind in 2016. With the commissioning of Meridian Wind Park, DTE now has 20 wind parks in its renewable energy portfolio. These projects, along with the company's 33 solar parks, generate enough clean energy to power more than 750,000 homes and represent an investment of more than $3 billion. DTE plans to add approximately 1,000 megawatts of new renewable energy each year starting in 2025, and as part of its CleanVision Integrated Resource Plan filed last fall, the company proposed adding an additional 15,000 megawatts of clean energy by 2042, giving DTE enough clean energy to power more than 4 million homes.

09:09 EDT Chicken Soup for the Soul signs expanded partnership with Dollar General - Redbox, a Chicken Soup (CSSE) for the Soul company, announced it signed an expanded partnership agreement with Dollar General (DG) to add 1,500 Redbox kiosks over the next two years. This will bring the number of Redbox kiosks at Dollar General to over 5,000 locations by the end of 2024, giving customers faster access to the newest movies.

09:08 EDT Broadcom announces delivery of Jericho3-AI - Broadcom announced that it has delivered Jericho3-AI, enabling the industry's highest performance fabric for artificial intelligence networks. Jericho3-AI revolutionizes AI networking with best-in-class capabilities such as perfect load balancing, congestion-free operation, ultra-high radix, and Zero-Impact Failover, all culminating in significantly shorter job completion times for any AI workload.

09:06 EDT Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 - Immuneering announced positive initial pharmacokinetic, PK, pharmacodynamic, PD, and safety data from the Phase 1 trial of IMM-1-104, which are being shared today in a poster presentation titled "Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors" at the American Association for Cancer Research, AACR, annual meeting. "We are very pleased to share initial PK, PD and safety data from our Phase 1 trial of IMM-1-104 in patients with advanced RAS mutant solid tumors, ahead of schedule," said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering. "We believe these data from the first patients dosed in our study demonstrate the PK, PD and safety profile necessary for deep cyclic inhibition - the proprietary and novel mechanism through which our therapies are designed to selectively impact cancer cells to a greater extent than healthy cells, regardless of the specific RAS mutation driving the tumor. The data show that we were able to reach significant levels of PK Cmax with the aim of breaking tumor addiction to the MAPK pathway, then rapidly clearing out drug with IMM-1-104's short half-life. These results position us to accelerate the dose escalation portion of our study, reaching potentially therapeutic levels of IMM-1-104 earlier than previously planned." The Phase 1/2a clinical trial is an open-label study designed to evaluate the safety, tolerability, PK and preliminary efficacy of IMM-1-104 in patients with advanced RAS mutant solid tumors. The Phase 1 portion of the study, which is being conducted at five clinical sites in the United States, is evaluating IMM-1-104 following a Bayesian mTPI-2 escalation design, which includes a dose escalation phase and dose evaluation phase to establish an optimized RP2D candidate. Following selection of the RP2D candidate, the Company expects to conduct a Phase 2a dose expansion phase to assess the safety and efficacy of IMM-1-104 at the RP2D in RAS mutated pancreatic, melanoma, lung and colorectal cancers.

09:06 EDT AMD joins AWS ISV Accelerate program - AMD has joined the Amazon Web Services Independent Software Vendor Accelerate Program, a co-sell program for AWS Partners - like AMD - who provide integrated solutions on AWS. The program helps AWS Partners drive new business by directly connecting participating ISVs with the AWS Sales organization.

09:05 EDT 374Water, Inc. demonstrates waste managment solution - Following on the heels of the first UN Water conference in 50 years, 374Water successfully demonstrated its AirSCWO supercritical water oxidation technology during SCWO week at its manufacturing partner's facility in Indiana. The event showcased the company's revolutionary waste management solution to hundreds of prospective customers, along with analysts and investors. The 3-day event, attended by over 400 guests featured a demonstration of the first commercial unit, set to be deployed in Orange County, CA, later this year; panel discussions; and plenty of time to "see the magic inside" and engage with experts on the technology. Attendees included over 200 potential customers, including several municipalities, representing over 10 countries.

09:04 EDT Jamf Holding expands collaboration with Microsoft, joins MISA - Jamf (JAMF) has announced that they are now a member of the Microsoft (MSFT) Intelligent Security Association, MISA. MISA is an ecosystem of independent software vendors and managed security service providers that have integrated their solutions with Microsoft security technology to help customers better defend themselves against increasingly sophisticated cyber threats. "We are thrilled to be a member of the Microsoft Intelligent Security Association and help bring security technology to customers to better defend themselves against increasingly sophisticated cyber threats," said Nick Amundsen, Strategy Senior Vice President, Jamf. "The Jamf Protect SIEM integration with Microsoft Sentinel is a powerful solution for organizations looking to gain better visibility into security events and streamline incident response."

09:03 EDT JLL acquires Kensington Capital Advisors, terms not disclosed - JLL announced it has wholly acquired Kensington Capital Advisors, a North Carolina-based derivatives and structured finance advisory firm. The acquisition includes Frame Financial Systems, a technology platform that will enable JLL to offer CRE investor clients a proprietary "software with a service" debt portfolio reporting and analytics solution. KCA and Frame's 23 employees will join the Capital Markets and JLL Technologies teams, and the technology product will be offered as a SwaS solution for investor clients looking to manage their corporate real estate debt portfolios more effectively.

09:02 EDT Comtech names Nicole Robinson chief strategy officer - Comtech announced the appointment of space industry veteran Nicole Robinson as a chief strategy officer. With nearly two decades of leadership experience in the space industry, Robinson brings expertise and differentiated knowledge across public, private, government, and commercial space sectors. Prior to joining Comtech, Robinson served as President of Ursa Space Systems.

09:01 EDT Bank of America sees Q2 expense around $400M-$500M lower than Q1 - Sees continued sequential expense declines in Q3, Q4.

09:00 EDT Bank of America continues to expect modest loan growth

08:58 EDT Lockheed Martin sees FY23 Aeronautics sales $26.5B-$26.8B - Sees FY23 Aeronautics operating profit $2.775B-$2.805B. Sees FY23 MFC sales $11.15B-$11.35B, operating profit $1.51B-$1.53B. Sees FY23 RMS sales $15.8B-$16.1B, operating profit $1.88B-$1.91B. Sees FY23 Space sales $11.55B-$11.75B, operating profit $1.09B-$1.11B. Comments taken from Q1 earnings conference call presentation slides.

08:52 EDT Iveco Group inaugurates new plant in Foggia - IVECO BUS inaugurated its new Foggia plant dedicated to the production of zero- and low-emission buses, in front of public authorities, trade union representatives, customers, suppliers and partners. According to the industrial plan, at full speed the new facility will employ 100 highly specialised people working lines equipped with the most advanced Industry 4.0 technologies. The production volume of the plant will be 1,000 vehicles per year: high-tech buses with zero-emission propulsion and low-emission propulsion. The plant emits zero net CO2 emissions. 100% of its energy comes from renewable sources, including over 1,000 photovoltaic panels that produce 640 MWh per year. The entire project focuses on reducing energy consumption and recycling, making use of high-performance construction materials, Intelligent LED lighting and rainwater reuse. Iveco Group is already present in Foggia with its FPT Industrial plant for the production of industrial engines and 1,600 employees, which make this one the largest industrial establishments in Puglia. The investment in the new plant of approximately 40 million euros - that will be partially offset by funds from the PNRR, the National Recovery and Resilience Plan - is strategic and puts two pillars of the PNRR into practice: "Green revolution and ecological transition" and "Infrastructure for sustainable mobility".

08:48 EDT Orbit International announces delay in filing 2022 annual report - Orbit International announced that the filing of its 2022 Annual Report with the OTC has been delayed beyond its extended due date of April 17, 2023, as additional time is needed to complete the audit of the acquired and ending inventory of its recently acquired Simulator Product Solutions LLC subsidiary and the preparation of the 2022 Annual Report. Mitchell Binder, President and CEO commented, "Some additional time is needed to complete our filing as our auditors complete their audit of the acquired inventory of SPS on January 3, 2022, as well as its ending inventory at December 31, 2022. Because the acquired inventory comprised a part of the purchase price of SPS, any one-time adjustments should have no material effect on the financial statements of Orbit. Furthermore, we do not expect any adjustments to SPS' ending inventory to have any material effect on the financial statements of the Company. Based on the amount of work expected to be completed by the Company and its auditors, we anticipate filing our 2022 Annual Report in approximately two to three weeks."

08:47 EDT Premier, Monaghan Medical sign AscenDrive contract - Monaghan Medical and Premier announced their agreement to a three-year contract, effective May 1, 2023, creating a partnership between two healthcare industry leaders. Through this partnership, Monaghan will provide Premier AscenDrive Program members with respiratory devices in two categories: Respiratory Therapy Medication Delivery devices and Oscillatory Positive Expiratory Pressure/Positive Airway Pressure devices. The agreement, specific to Premier's committed AscenDrive performance group, recognizes the value of Monaghan's medical devices in treating COPD, asthma, and respiratory illness. The signed agreement acknowledges Monaghan's reputation for both industry-leading technology and proven clinical outcomes. Monaghan's devices consistently show evidence of better patient outcomes and are gold-standard medical devices. Monaghan's respiratory devices also align with Premier's desire to drive process efficiencies and value-driven healthcare spending.

08:44 EDT Iteris awarded two-year contract for traffic signal timing by ODOT, no terms - Iteris announced that it has been awarded a two-year contract for statewide traffic signal timing and operation by the Ohio Department of Transportation ODOT , representing continued demand for Iteris' specialized consulting services to support another important mobility infrastructure project in a key geographic market. Under the contract, Iteris will develop signal timing plans for 53 key signalized intersections in Northeast Ohio, with additional locations throughout the state expected to come at a later date. ."

08:43 EDT Bebuzee announces launch of revised website of Super App - Bebuzee announced the launch of its accompanying revised website of the Super App. Joseph Onyero, CEO, said: "We are very excited to start rolling out this product that we have put so much effort on. We are confident that this super app will gradually become an integral part of our daily lives in North America, Europe, Africa and South America. Not all the products on Bebuzee super app are on the website at present but most of the products are there."

08:40 EDT Datasea expands business with 5G recharge payment platform - Datasea announced that on February 16, 2023, Hangzhou Shuhai Zhangxun Technology, a subsidiary of the Chinese operating company contractually controlled by the Company, has entered into a cooperation agreement with Hangzhou Chongda Technology to enhance 5G messaging recharge services in the Chinese market. Under the agreement, Chongda can purchase up to 1.1M virtual recharge cards of various denominations for 5G messaging within 12 months commencing from February 16, 2023, with a maximum total value of approximately USD 29.81M. Since the date of the agreement until the date of this announcement, Shuhai Zhangxun has provided end-users with 5G messaging recharge services worth approximately USD 0.85M, demonstrating the Company's unwavering commitment to the 5G messaging market in China. Datasea's CEO, Zhixin Liu, expressed her satisfaction with the collaboration's progress, emphasizing the importance of identifying potential customers that need their 5G messaging delivery services, and providing efficient and stable 5G messaging services to customers quickly.

08:37 EDT Bank of America deposits continuing to perform well, says CEO

08:37 EDT BofA CEO: U.S. consumer finances remain generally healthy

08:36 EDT Bank of America continues to expect shallow recession, says CEO - Comments taken from Q1 earnings conference call.

08:36 EDT Goldman Sachs slips 3% to $328.60 after Q1 results - Shares of Goldman Sachs are down 3.3% or $11.08 at $328.60 in pre-market trading after the company's Q1 results.

08:35 EDT Fluor signs MOU with Longview to serve as engineering, construction partner - Fluor announced that it has signed a memorandum of understanding, or MOU, with Longview Fusion Energy Systems to serve as its engineering and construction partner in designing and planning laser fusion energy for the global energy market. At full capacity, Longview's laser fusion power plants are slated to provide carbon-free, safe, economical and sustainable energy that can power the needs of a small city or provide process heat or power to drive industrial production of the materials needed for operational necessities like steel, fertilizer and hydrogen fuel.

08:34 EDT Imax and Megarama add three locations in France and Morocco - Imax and French exhibition company Megarama announced an agreement for three new Imax systems in France and Morocco. The new deal will more than triple Imax's footprint with Megarama and bring the number of Imax systems in France to 29, including 23 currently open and another 6 set for installation. Two of the new Imax with Laser locations will be in France - in Givors and Boulogne-Sur-Mer - and one in Rabat, the capital city of Morocco. With this new deal, Megarama becomes Imax's second biggest commercial client in France.

08:33 EDT Lisata, WARPNINE announce first patient treated in iLSTA trial of LSTA1 - Lisata Therapeutics and WARPNINE Incorporated announced the treatment of the first patient in the iLSTA Trial of Lisata's LSTA1 in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma. "Dosing the first patient in our iLSTA Trial of LSTA1 in patients with pancreatic cancer in Australia is an important step in our mission to create new hope for patients by providing meaningful treatments to those with few remaining alternatives. We believe that LSTA1 represents a new treatment option for these patients who haven't been fully served by standard-of-care alone," stated Kristen Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. "We are thrilled by the progress being made to help advance LSTA1 through the clinical trial process and are grateful to WARPNINE for their financial and operational support."

08:32 EDT Phunware receives notice of allowance for patent on geofence event predictions - Phunware announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the Company's US patent application 17/362,765 titled Method and Apparatus for Geofence Event Predictions. This capability will significantly enhance the capabilities of Phunware's location-based services and enable brands to deliver personalized, context-aware experiences to their users. The patent covers a method for predicting geofence events by retrieving non-contemporaneous geofence predictor data of a mobile device, including past and future geographic data. By analyzing this data, along with geofence data of the mobile device, the system develops a future geofence event prediction, including a latitude, longitude, time and confidence level for the prediction. This innovative technology allows businesses to better understand their users' behavior patterns and preferences, ultimately improving the overall user experience. By detecting patterns in past geofence events and incorporating future engagement opportunities, Phunware's geofence event prediction technology enables businesses to deliver highly targeted, timely and relevant content to users based on their anticipated location and activities.

08:31 EDT Guardant Health gets Medicare coverage for Guardant360 Response test - Guardant Health announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program has conveyed coverage for the Guardant360 Response test. Guardant360 Response is the first blood-only test that enables doctors to track molecular response through changes in circulating tumor DNA levels, to get an early indication of metastatic or advanced cancer patient response to immune checkpoint inhibitor therapy. Following this decision, the Guardant360 Response test is now covered for fee-for-service Medicare patients in the U.S. with metastatic or inoperable solid tumors who are on an immune checkpoint inhibitor therapy. The coverage includes a Guardant360 CDx or LDT test before initiating therapy to establish a ctDNA baseline and a Guardant360 Response test 4 to 10 weeks after the therapy has been initiated to measure the change in ctDNA level. "We are pleased that Medicare has taken this important step to make treatment response monitoring more widely available in order to assist oncologists in making more informed therapeutic decisions for their patients with solid tumor cancers," said Helmy Eltoukhy, Guardant Health co-CEO.

08:27 EDT Ra Medical Systems CEO Will McGuire resigns, David Jenkins named interim CEO - Ra Medical Systems announced the resignation of its CEO, Will McGuire, for personal reasons. The resignation will be effective April 28, 2023. In conjunction with his resignation as CEO, Mr. McGuire is also resigning from the RMED board of directors.The RMED board of directors, as part of its governance commitment, last month established a committee for examining a transition at the CEO level. Mr. David Jenkins, the Company's Executive Chairman of the Board, will serve as Interim CEO until a full-time replacement is named.

08:26 EDT Cuentas announces compliance with all Nasdaq continued listing rules - Cuentas announced that the Company has received formal notification from the NASDAQ Hearings Panel that the Company has evidenced full compliance with the minimum bid price requirement and all other applicable criteria for continued listing on The NASDAQ Stock Market, that all compliance matters have been resolved, and that the Panel has closed the Company's compliance file. To evidence compliance with the minimum bid requirement, the Company needed to evidence a closing bid price of at least $1.00 per share for a minimum of ten, but generally not more than 20, consecutive business days. The Panel has determined to continue the listing of the Company's securities on The NASDAQ Stock Market and the Company has no further deficiencies.

08:25 EDT SOBRsafe enters distribution agreement with Fox Group - SOBR Safe signed a distribution agreement with previously announced customer the Fox Group. Through its commercial driver training portfolio, the Fox Group has established relationships with significant employers in key SOBRsafe markets such as oil and gas, mining and trucking. The Fox Group joins Alco Prevention Canada as SOBRsafe's initial Canadian representatives, rounding out a group of four new distributors the Company has signed in 2023. SOBRsafe now has 13 North American distributors.

08:24 EDT Matinas BioPharma announces presentation on MAT2203 at EECMID - Matinas BioPharma announces that Marisa Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases Internal Medicine at the University of Michigan and her team delivered an oral presentation earlier today at the 33rd European Congress of Clinical Microbiology & Infectious Diseases, EECMID, in Copenhagen discussing MAT2203's clinical impact in treating a compassionate use patient suffering from Rhodotorula mucilaginosa, a rare and opportunistic invasive fungal infection. Key elements of Dr. Miceli's team presentation included: Rhodotorula are a genus of pigmented yeasts and represent a rare, but opportunistic and emerging threat often highly resistant to antifungal therapy. The patient was at risk of amputation of her foot where the infection was located and was generally unable to walk. The patient began treatment with liposomal IV-administered amphotericin B but developed serious kidney toxicities attributed to the use of IV-amphotericin B. As a result, treatment with IV-amphotericin B was discontinued and Dr. Miceli applied to Matinas' Compassionate Use Expanded Access Program for treatment with MAT2203. The patient was admitted for monitored initiation of MAT2203 with a dosing regimen of 300mg, four times a day. Following initiation with MAT2203, the patient's renal function improved and remained at baseline throughout treatment. While taking MAT2203, the patient experienced none of the electrolyte abnormalities evident while taking IV-amphotericin B. The patient received MAT2203 daily for six months and ended therapy in January 2023 following complete clinical resolution of the fungal infection while regaining the use of her foot

08:21 EDT WWE & Fanatics expand partnership to include global event retail merchandise - WWE and Fanatics announced an expansion of their existing comprehensive, long-term sports and entertainment partnership, which will now see Fanatics assume operations of WWE's global event merchandise business. The deal will kick off on May 1 before WWE's premium live event, Backlash . Under the expanded partnership, Fanatics Commerce, the company's e-commerce, licensed merchandise and physical retail operations division, will manage the on-site event retail experience for WWE's annual calendar of 300-plus events, including premium live events such as WrestleMania, Royal Rumble and SummerSlam. Fanatics will work closely and collaboratively with world-class teams at WWE who previously operated the event retail business in-house for decades to optimize the event shopping experience for its growing global fanbase. This includes curating an enhanced in-venue product offering with more localized merchandise collections, creating innovative event retail stores and experiences, as well as utilizing Fanatics-operated team stores during various live events. Fanatics holds physical retail partnerships with more than 50 professional and college teams across several sports. The expansion follows strong commercial results for WWE across its retail channels in 2022, including record-breaking demand for WWE merchandise.

08:21 EDT Nuvectis Pharma recaps poster presentation highlights on NXP800 - Nuvectis Pharma provided highlights from the poster presentation of NXP800 that took place yesterday at the American Association for Cancer Research Annual Meeting 2023 in Orlando, FL. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "Cancer of the bile duct, or cholangiocarcinoma, is a serious unmet medical need for which new treatment options are greatly needed. With approximately 10,000 new cases per year in the United States, the clinical management of CCA is complex, with only about 30% of patients eligible for surgical resection and the rest with unresectable disease, which carries a dismal prognosis with a median survival of less than 1 year. Unfortunately, approximately 60% of the patients that do undergo surgical resection experience disease recurrence and face similar outcomes." Mr. Bentsur concluded, "We are excited about the data generated as we continue to evaluate clinical development opportunities for NXP800."

08:19 EDT Auddia announces interm bridge financing, withdraws S-1 registration statement - Auddia has secured bridge financing from insiders and other investors on more favorable terms than are currently available in the public capital markets. The Company believes this interim financing will bridge to potential critical milestone achievements that include improved faidr usage metrics and executing business development agreements with one or more streaming AM/FM radio station aggregators that could significantly accelerate Auddia's growth trajectory. The bridge financing includes an increase in its existing $2 million non-convertible, term debt, from an existing affiliate investor to $2.75 million, as well draw downs on its previously disclosed $10M equity line, which includes more favorable terms than other currently available public financing alternatives. In light of the successful interim financing, the Company will withdraw its pending S-1 registration statement for a proposed secondary stock offering. The Company has explored numerous potential acquisition targets over the past year and a half and continues to explore new opportunities. At present, the Company is in advanced active discussions with three properties and is targeting to execute one or more agreements in the near term. Based on diligence to date the Company believes the three target properties under active discussion aggregate to approximately $6.5M in current annual revenue with greater than 50% free cash flow. Current revenue is primarily from digital ad revenue and software sales. The Company believes existing digital ad revenue from these properties can be increased through active management to provide immediate synergies. The total user base listening to AM/FM streams across all three properties is over 10 million monthly active users worldwide, with 1.1 million being U.S. users that represent a free tier that can be offered a commercial free premium experience through faidr, resulting in new subscription revenue to Auddia.

08:17 EDT Dare Bioscience announces publication of data from Phase 1 clinical trial - Dare Bioscience announced that Climacteric, the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical trial of DARE-HRT1, an investigational ethylene vinyl acetate copolymer intravaginal ring designed to release bio-identical 17beta-estradiol and progesterone over 28 days. DARE-HRT1 is being developed for the treatment of moderate-to-severe vasomotor symptoms, VMS, due to menopause in women with intact uteri. Hormone therapy is used to treat VMS and genitourinary syndrome associated with menopause. DARE-HRT1 has the potential to be the first FDA-approved product to offer vaginal delivery of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient monthly format. The North American Menopause Society's guidance on hormone therapy states that dosing estrogen and progestogen in combination may offer important benefits to women, and NAMS observed that non-oral routes of administration may offer advantages over orally administered therapies. Approximately 30 healthy, postmenopausal women participated in the open-label, three-arm Phase 1 study. The primary objective of the study was to assess the pharmacokinetics from the two dosage strengths of the DARE-HRT1 IVRs. The secondary objective of the study was to assess the safety of the IVRs while the exploratory objectives were to assess usability and participant tolerability of the IVRs. The study demonstrated that the DARE-HRT1 IVRs, in general, were safe and well tolerated in healthy postmenopausal women and treatment emergent adverse events profiles were comparable between the DARE-HRT1 groups and the reference oral regimen group.

08:17 EDT Arcutis Biotherapeutics announces FDA acceptance of roflumilast foam NDA - Arcutis Biotherapeutics announced the U.S. Food and Drug Administration has accepted for review the company's new drug application for roflumilast foam 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. The application was assigned a Prescription Drug User Fee Act target action date of December 16, 2023.

08:16 EDT Shoals Technologies to supply BLA+ for 120 MW solar project - Shoals Technologies Group announced it has been awarded a 120 MW contract to supply its BLA+ solution to a utility-scale solar project in Western Australia. The BLA+ solution, formerly known as BLA 2.0, is a bundled offering that combines the BLA system with all the components required to attach the BLA to the racking system, including wire management, support wire and tensioning systems to create a single integrated offering. Deliveries for the project are expected to be completed by Q4 2023.

08:14 EDT Beam Global receives order fo EV ARC solar-powered EV charging systems - Beam Global announced a global automotive brand has placed an order for EV ARC(TM) solar-powered EV charging systems.

08:12 EDT GrowGeneration acquires store in Jackson, Michigan, no terms - GrowGeneration announced the acquisition of inventory and equipment from Mighty Grow, a family owned and operated business located in Jackson, Michigan serving the gardening community for over 10 years. As a part of the transaction, GrowGen also took over the existing store location at 2418 W. Michigan Ave. Jackson, MI. Darren Lampert, Co-Founder and Chief Executive Officer of GrowGen, said, "We are excited to expand our retail footprint in Michigan with this strategic transaction which represents our eighth location in the state. Mighty Grow has successfully served the broader Jackson growing market for over 10 years through focusing on customer service and offering high quality supplies to its customers. We look forward to continuing this location's strong legacy and providing the same caliber of service and product offerings to the local and surrounding growing markets." Lampert continued, "GrowGen remains committed to providing high-quality products and having the largest product selection, best service, and most knowledgeable grow professionals in the industry. This transaction supports those commitments and enhances our overall portfolio of stores to best serve both our commercial and home-grow customers."

08:12 EDT FOXO Technologies COO Taylor Fay resigns - FOXO Technologies announced the resignation of Taylor Fay as COO of the company, effective April 28.

08:11 EDT Nisun International enters into wheat flour sales and purchase agreement - Nisun International's controlled affiliate, Fintech Supply Chain Management Shandong, has entered into a wheat flour sales and purchase agreement with Binzhou Zhongyu Food, a manufacturer in China with a green and environmental circular economy industrial chain from wheat seeds to deep production. The company expects to accelerate its business growth in the market of wheat flour through the execution of the agreement. China is the largest wheat consumer and producer in the world. Pursuant to the Agreement, Zhongyu Food would notify Shandong Fintech of the purchase quantity, delivery date, and other requirements one day in advance and pay the full amount for the goods within 10 business days from the delivery date. It is estimated that by the end of 2023, the scale of cooperation will exceed RMB 600M, approximately $87.3M.

08:11 EDT Adverum Biotechnologies granted ILAP designation for Ixo-vec in Wet AMD - Adverum Biotechnologies announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency as granted Ixo-vec, an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway. The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence and the National Health Service England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom.

08:10 EDT Humacyte announces publication of preclinical study on HAV to expanded ePTFE - Humacyte announced the publication of a preclinical study in the Journal of Trauma and Acute Care Surgery comparing the use of its Human Acellular Vessel, HAV, to expanded polytetrafluorethylene, ePTFE, grafts for vascular repair following arterial trauma. In the preclinical study the HAV performed better than ePTFE on multiple indices. In this comparative preclinical study, 36 pigs were randomly assigned to treatment groups receiving either the HAV or an ePTFE graft to reconstruct a severed iliac artery after vascular trauma. The animals were monitored for 28 days and routinely assessed for recovery of hind limb function, graft patency, and circulating biochemical markers of tissue ischemia and reperfusion injury. At the conclusion of the study, the HAV and ePTFE implants were removed and histologically evaluated for host cellular response. The data observed in this preclinical study indicate that the HAV performed better than ePTFE on multiple indices, including recovery of limb function after six hours of ischemia and conduit patency. In addition, the HAV showed no incidence of infection, degradation, aneurysm or mechanical failure. Host recellularization of the HAV conduits was observed to be greater than that of ePTFE grafts. "We believe the results of this study underscore the potential of the HAV to save the lives and limbs of those suffering from vascular injury and peripheral tissue ischemia," said Rob Kirkton, Ph.D., Director of New Product Development at Humacyte and lead author of the publication.

08:08 EDT HASI makes equity investment in solar-plus-storage portfolio in California - HASI and ForeFront Power, a developer and asset manager of commercial and industrial-scale solar energy and battery storage projects, have entered into a follow-on equity investment for a portfolio of distributed solar and solar-plus-storage projects located across California. The transaction, which reached financial close on March 30, builds upon an initial co-sponsor equity investment for a separate U.S. distributed solar portfolio that HASI made with ForeFront Power in 2022. The portfolio comprises 48.5 MW-DC of commercial and industrial ground-mounted, carport, and rooftop solar, including several projects paired with battery storage totaling 3.7 MW. Approximately 36 MW of the distributed assets are mechanically complete and were funded at financial close, while the remaining projects will be funded upon completion through year-end.

08:08 EDT Taoping enters long-term strategic cooperation agreement with Wuxuan County - Taoping announced the company has entered into a long-term strategic cooperation agreement with Wuxuan County, Guangxi Province, with a potential market opportunity of $80M valuation for off-grid wastewater treatment solution alone. Under the Agreement, Taoping expects to provide customized intelligent, Cloud-based product solutions, including its exciting new Blue Box off-grid wastewater treatment solution, IoT Smart Rest Station, fully autonomous street sweeper and smart large screen displays. Wuxuan County is an important tourism city with an estimated 458,600 residents. By gaining access to Taoping's modular solutions, Wuxuan County's residents will be able to benefit from improved efficiency, convenience, and cost-effectiveness in various aspects of their daily lives. This follows news of Taoping's April agreement to provide similar services to China's Zhaoyuan City, which has more than 500,000 estimated residents.

08:07 EDT DMG Blockchain Solutions purchases new bitcoin miners - DMG Blockchain Solutions announces new miner purchases. These purchases are additive to its previously announced 1 EH/s of Bitcoin miner purchases, all of which have been delivered except its final tranche of 300 Bitmain S19 XPs. The purchases include 350 Bitmain S19 Pro, 350 Bitmain S19 XP and 850 Bitmain S19j Pro+ miners, which total an additional 1,550 units contributing 188 PH/s. The 350 Bitmain S19 Pros were a spot deal and have already arrived; the remaining miners will be added in the coming months to the DMG's Christina Lake data center. The Company is discussing further purchases with Bitmain and other suppliers. The additional hashrate is subject to the receipt, installation, and operation of these additional miners. As previously announced, DMG has purchased over 40 megawatts of crypto mining containers. The company is now finalizing shipping logistics. The first containers are expected to arrive in early July 2023 and continue arriving through September 2023

08:06 EDT Dominari Holdings unit acquires asset management team - Dominari Holdings announced that its wholly-owned subsidiary, Dominari Securities LLC, has added an asset management team that manages over $700M in client assets to its organization. This is the first significant acquisition since the division officially launched earlier this month after the purchase of the broker-dealer and registered investment adviser divisions of Fieldpoint Private Securities.

08:05 EDT Leidos awarded a new prime contract from U.S. Marine Corps - Leidos was recently awarded a new prime contract to develop an uncrewed aircraft system that can autonomously resupply forward-deployed ground forces. The firm-fixed-price, multiple-award contract has a period of performance of 18 months to build a single prototype for the Marine Corps. Under the contract, Leidos will develop, deliver and demonstrate an autonomous medium unmanned logistics system - air prototype. The prototype will then be used to perform a logistics distribution mission at the tactical edge of the battlefield. The goal of the project is to demonstrate a prototype UAS that can carry a logistics payload between 300 and 600 pounds to a combat area with a radius of 25 to 100 nautical miles. The work will be performed at locations in Colorado, Ohio, Oregon, California, Nevada and Arizona.

08:05 EDT Madrigal Pharmaceuticals receives BTD from FDA for Resmetirom - Madrigal Pharmaceuticals announced that resmetirom has received Breakthrough Therapy designation, BTD, from the U.S. Food and Drug Administration for the treatment of patients with NASH with liver fibrosis. The Company also announced that the outcomes portion of the Phase 3 MAESTRO-NASH biopsy trial has completed enrollment. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, "The Breakthrough Therapy designation for resmetirom reflects the FDA's recognition of resmetirom's potential in the treatment of NASH as a serious, life-threatening condition and an important area of investigational drug development. It also reinforces our confidence in our regulatory strategy as we approach the new drug application (NDA) filing for resmetirom, which remains on track for Q2 2023. The filing is supported by the positive outcomes on reduction of liver fibrosis and resolution of NASH from the 52-week serial liver biopsy portion of MAESTRO-NASH."

08:03 EDT Assembly Biosciences announces additional data from Phase 1a trial on ABI-4334 - Assembly Biosciences provided an update of results from the final multiple-dose cohort in the ongoing Phase 1a study of its investigational next-generation, highly potent hepatitis B virus core inhibitor, ABI-4334, and announced it will evaluate partnering opportunities for its core inhibitor portfolio and prioritize its expanded virology pipeline. "We are encouraged by the promising clinical profile of our most potent core inhibitor candidate, 4334, and its potential to reach the clinical exposures needed for both potent antiviral activity and inhibition of cccDNA formation," said Jason Okazaki, chief executive officer and president of Assembly Bio. "While we are enthusiastic about these results and the antiviral activity shown in our Phase 1b study of our other next-generation core inhibitor, 3733, in HBV patients, we recognize that demonstrating the ability of next-generation core inhibitors to inhibit cccDNA formation in the clinic, which we view as a critical part of HBV cure, will require longer-duration Phase 2 studies. Because of this, we believe partnering our core inhibitor portfolio would enable additional opportunities for further clinical development for this compelling mechanism aimed at achieving a functional cure for HBV, including opening up other avenues for combination approaches." Assembly Bio's expanded virology research pipeline unveiled in 2022 focuses on differentiated programs against validated clinical targets for HBV/hepatitis delta virus and herpesviruses. With the reprioritization of programs, Assembly Bio's estimated cash runway extends into the third quarter of 2024. 4334 Clinical Data and Development Update: The Phase 1a clinical trial for 4334 is a randomized, blinded and placebo-controlled study evaluating the safety, tolerability and pharmacokinetics of 4334 following single ascending dose and multiple ascending dose administration in healthy subjects. Dosing has been completed for all subjects in all four single-dose cohorts , two multiple-dose cohorts of 100 mg and 200 mg and one food effect cohort at 200 mg. Based on data available for the single-dose and multiple-dose cohorts through April 17, 2023, 4334 continued to show a half-life supportive of once-a-day dosing.

07:56 EDT Lordstown enters agreement with Amerit Fleet Solutions for service, warranty - Lordstown Motors and Amerit Fleet Solutions entered into an agreement for Amerit to provide service and maintenance to Lordstown's commercial fleet customers. The Lordstown Endurance began commercial production at the Foxconn EV Ohio assembly plant in Q3 2022. Sales started in Q4 2022. Production and deliveries resumed in April 2023 after a pause earlier in the year to address supplier quality issues and are expected to continue at a very low pace. Under the terms of the agreement, the two companies will jointly provide EV service and warranty for the Lordstown Endurance in key states allowed by law, as well as future vehicles developed by Lordstown in collaboration with the Foxconn EV ecosystem. Amerit is executing plans for the strategic rollout of service locations aligned with Lordstown's launch plan for initial fleet customers. Prior to the launch of services, Amerit service technicians will complete an extensive safety training program as well as Lordstown's training curriculum for the Endurance and other future vehicles.

07:46 EDT Fairfax Financial provides preliminary estimate on effect of IFRS 17 - Fairfax Financial Holdings announces its preliminary, not finalized, unaudited estimate of the effect of IFRS 17, the new accounting standard which was required to be adopted on January 1, 2023 for insurance contracts, on common shareholders' equity as at December 31, 2022. The finalized information will be presented in the Company's 2023 first quarter unaudited financial results, which will be released after the close of markets on Thursday, May 11. The Company's preliminary estimate of the effect of IFRS 17 on common shareholders' equity is that it will increase common shareholders' equity as at December 31, 2022 by approximately $2.2 billion, primarily reflecting the introduction of discounting net claims reserves, partially offset by the tax effect of the measurement changes and other of approximately $0.8 billion. Although IFRS 17 brings considerable changes to the measurement, presentation and disclosure of the Company's insurance and reinsurance operations, it will not affect the Company's underwriting strategy, its prudent reserving, management's use of the traditional performance metrics of gross premiums written, net premiums written and combined ratios, or the amount of the Company's cash flows.

07:38 EDT Jushi announces support for Virginia's passage of medical cannabis bills - Jushi Holdings announced support and appreciation for the Virginia General Assembly's passage of medical cannabis and cannabinoid product-related bills amended by Governor Glenn Youngkin. Last week, the Virginia General Assembly gathered to take up seventy-eight bills amended by the Governor, including medical cannabis bills designed to enhance program accessibility for patients, improve operational efficiency for pharmaceutical processors and fully transfer regulatory oversight to the Virginia Cannabis Control Authority. Most patient-focused and operations-based changes will become effective on July 1, 2023, and CCA will take over regulating the program on January 1, 2024. With respect to broader cannabis-related matters, the General Assembly also approved Governor Youngkin's amendments to bills aimed at bringing unauthorized, intoxicating cannabinoid products under a regulatory framework. These products are easily accessible in every community across the Commonwealth and commonly used as a substitute for adult-use cannabis. Currently, these products are not subject to regulatory oversight or consumer safety protections and have seriously sickened many Virginians - including hundreds of young children. "While we support the intention of this legislation to protect public health and safety, Jushi respectfully maintains that any effort to improve the status quo that does not incorporate a retail adult-use cannabis market will ultimately be ineffective," said said Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi Holdings Inc. "We are disappointed Virginia missed an opportunity to advance bills expanding legal access to safe, tested adult-use cannabis products this Session, but appreciate that this year's cannabinoid product-related bills represent a step in the right direction for Virginians," Cacioppo said.

07:35 EDT Dragonfly Energy enters battery partnership with Airstream - Dragonfly Energy announced it has partnered with Airstream, the manufacturer of the iconic riveted aluminum travel trailers, to provide Battle Born Batteries as standard equipment in the Pottery Barn Special Edition Travel Trailer and Classic Travel Trailer models and as an optional upgrade on the REI Co-op Special Edition Basecamp Travel Trailer. Battery anxiety has long been a pain point amongst consumers in the RV Industry, however with this power upgrade from Dragonfly Energy, Airstream customers now have access to a solution that allows them to enhance their camping experience. "We are honored to see our lithium power solutions as both standard and factory-installed upgrades on such an iconic brand," Dr. Denis Phares, CEO of Dragonfly Energy, said. "We are excited about the collaborative opportunities that our expanded partnership will enable in the future. And I would also like to thank Airstream for recognizing all of the hard work put forth by our employees and suppliers by naming us a Five Rivet Supplier."

07:35 EDT Lockheed Martin backs FY23 cash from operations greater than, equal to $8.15B - Backs FY23 free cash flow greater than, equal to $6.2B.

07:33 EDT Lockheed Martin reports Q1 cash from operations of $1.6B; free cash flow $1.3B

07:33 EDT Intelligent Bio Solutions secures UK patent for Intelligent Fingerprinting tech - Intelligent Bio Solutions announced that the Company has been granted a patent in the United Kingdom (UK) relating to its Intelligent Fingerprinting Drug Screening System DSR-Plus Cartridge Reader. This is the Company's 13th patent, which further strengthens the protection of its unique and proprietary drug screening technology. UK Patent No: GB2592432, relates to the proprietary lateral flow test strip reading capability within the Company's latest DSR-Plus cartridge reading unit. Designed and manufactured in the UK, the cartridge reader features a compact and portable specification that enables even simpler and faster drug testing. It provides organizations with rapid drug screening support wherever and whenever it's needed. The DSR-Plus reader has been designed with no moving parts, ensuring resiliency when customers transport it between different sites, while improved battery life boosts screening productivity for human resources teams. The non-invasive Intelligent Fingerprinting system comprises a small, tamper-evident drug screening cartridge onto which ten fingerprint sweat samples are collected in under a minute, before the portable DSR-Plus reader provides an on-screen result in less than ten minutes. The system can be used in-house and screens the sweat for recent drug use, including cannabis, cocaine, opiates, and methamphetamine.

07:30 EDT Goldman Sachs reports Q1 FICC revenue $3.93B, down 17% y/y

07:29 EDT Wildpack Beverage announces late filing of annual financial statements - Wildpack Beverage announced the Company's potential delay in filing its annual financial statements for the year ended December 31, 2022 and related management discussion and analysis and certifications, and the CEO and CFO certificates delating to the Financial Statements beyond the prescribed filing deadlines. The Company's potential delay in filing its Required Filings on time is due to the Company's recent change of auditor, whereby a successor auditor has not yet been appointed. The Company is in the process of appointing a successor auditor, and upon appointment of such successor auditor the Company intends to promptly coordinate the financial audit of its annual financial statements and associated filings with the successor auditor. Considering the foregoing, it is the Company's view that should the Required Filings not be filed by May 1, 2023, then, the present circumstances warrant the imposition of a management cease trade order as contemplated under National Policy 12-203 - Management Cease Trade Orders. The Company has applied for a MCTO, however there is no assurance that it will be granted. The Company's board of directors and its management are working expeditiously to meet the Company's obligations to file the Required Filings. The Audit Committee is working diligently to appoint a successor auditor, and to work with such successor auditor to complete the Financial Statements. The Company expects to be in a position to issue and file the Required Filings by no later than June 30, 2023. Until then, the Company has confirmed that it intends to satisfy the provisions of the alternative information guidelines described in sections 9 and 10 of NP 12-203 for so long as it remains in default for failure to file the Required Filings. Should the Company fail to file the appropriate Default Status Reports as prescribed by NP 12-203, the securities commissions or regulators may, as a result of such failure, impose an Issuer Cease Trade Order. The Company confirms that it is not subject to any insolvency proceeding as of the date hereof. The Company also confirms that there is no other material information concerning the affairs of the Company that have not been generally disclosed as of the date herein.

07:16 EDT Laser Photonics receives order from Gateway Clipper - Laser Photonics announced it received an order from Gateway Clipper, an operator of sightseeing and dinner cruises on Pittsburgh's Three Rivers.

07:13 EDT Arch announces results of dose escalation human trial for LSALT peptide - Arch Biopartners announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia. LSALT peptide is the Company's lead drug candidate for treating inflammation in the lungs, liver and kidneys and Arch intends to use the new maximum dose in designing a Phase II trial targeting cardiac surgery-associated acute kidney injury. The new safety data will be included in an Investigational New Drug Application to the U.S. FDA, to be submitted in relation to the CS-AKI trial in due course. The dose escalation human trial was performed at the Alfred Hospital in Melbourne, Australia.

07:11 EDT Sintana provides update on VMM-37 joint operating agreement - Sintana Energy reports that ExxonMobil sent Patriot Energy Oil and Gas, a subsidiary of the Company, a notice stating that, based on the terms of the Joint Operating Agreement between ExxonMobil and Patriot, it had decided to withdraw from the JOA as of May 31, 2023. The notice also states that ExxonMobil will withdraw from the Contract with the Agencia Nacional de Hidrocarbons, effective after obtaining required Government approvals. Both the JOA and Contract pertain to the 43,158 acres property known as the VMM-37 block which is in Colombia's Middle Magdalena Valley Basin. The Company fully reserves its rights under the contracts governing VMM-37 and applicable laws and regulations.Further updates will be provided with respect to these matters as additional information becomes available.

07:09 EDT Tilray launches PROJECT 4:20, new limited release craft beer - Montauk Brewing announced the launch of PROJECT 4:20, a new limited release craft brew created to celebrate and support local green charities during Earth Month and beyond. Montauk Brewing also invites fans to celebrate the launch of PROJECT 4:20 at the Brew Barn in Montauk, New York, on April 20, 2023. Vaughan Cutillo, Founder, Montauk Brewing Company, said, "As a true Montauk brand, we wanted to create something new that purely focused on supporting our passion for the ocean, environment, and local communities. PROJECT 4:20 is a new and important initiative for us that we are extremely proud of and plan to launch beyond the northeast and across the country."

07:08 EDT Immunocore presents new KIMMTRAK data on association between ctDNA, survival - Immunocore has presented four posters with KIMMTRAK data in HLA-A*02:01 patients with metastatic uveal melanoma, at the 2023 American Association for Cancer Research Annual Meeting 2023. Circulating tumor DNA reduction by week 9 was observed in 88% of mUM patients treated as first-line and 71% in previously treated patients; in both trials, this reduction was associated with longer overall survival. ctDNA clearance was also higher in first-line patients compared to second-line patients. ctDNA clearance in the Phase 3 trial was associated with 84% 1-year OS. The final analysis from the Phase 2 trial in previously treated mUM, after 46 months of follow-up, showed a median OS of 16.8 months - consistent with previous data updates. The landmark OS rates from the trial were approximately double historical rates in this patient population, as reported in two meta-analyses. The third poster provides a pooled analysis from 3 clinical trials in 12 mUM patients with orbital disease. Tebentafusp demonstrated preliminary signals of activity in intra-ocular lesions, supporting KIMMTRAK's use in patients with unresectable uveal melanoma. The fourth poster shares in vitro data potentially explaining how tebentafusp may lead to OS benefit even in tumors with heterogenous gp100 expression.

07:06 EDT Surface Oncology presents new preclinical data on SRF114 - Surface Oncology announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research, AACR, Annual Meeting 2023 in Orlando, Florida. The data will be presented in a poster session being held today. Summary of key data: In human CCR8 knock-in mice, SRF114, a fully human antibody targeting human CCR8, conferred robust anti-tumor activity and reshaped the tumor microenvironment towards a proinflammatory milieu. In different in vivo models, SRF114 monotherapy or treatment with a murine surrogate antibody promoted expansion of CD8+ effector T cells and increased the production of pro-inflammatory molecules including IFNgamma, TNFalpha, and granzyme A in a checkpoint-resistant tumor model. Anti-CCR8 therapy resulted in depletion of tumor Tregs without impacting peripheral lymphoid Treg cell populations and led to increases in the levels of co-stimulatory molecules CD80 and CD86 in a subset of tumor myeloid cells. Anti-CCR8 and anti-PD-1 combination therapy increased tumor immune cell infiltration, cytokine production and improved overall survival in a checkpoint inhibitor resistant melanoma model.

07:05 EDT Sernova says proxy advisory firms recommend shareholders vote for nominees - Sernova announces that a second independent, third-party proxy advisory firm, Glass Lewis & Co. has recommended Sernova's shareholders vote FOR all of Sernova's management nominees using only management's WHITE proxy. Glass Lewis also recommended that shareholders vote FOR the appointment of KPMG LLP as Sernova's auditors and FOR the resolution to amend the Corporation's stock option plan and DSU Plan. Glass Lewis recommended that shareholders vote FOR the resolution to amend the Corporation's stock option plan and DSU Plan, as the proxy advisory firm believes the terms of the plan are in line with the majority of similar equity-based plans of TSX issuers. Glass Lewis' view is that the plan will serve to strengthen the alignment of company and shareholder interests. The Corporation believes that encouraging its executive officers, senior management and employees to become shareholders is the best way of aligning their interests with those of its long-term shareholders. As a result, executive officers management and employees are provided with the opportunity to participate in the appreciation of the Corporation's share price, through Sernova's equity compensation incentive plan.

07:05 EDT Xeris Biopharma announces issuance of U.S. patent covering XeriSol formulations - Xeris Biopharma Holdings announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled 'METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.' The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris' Gvoke product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations. "Xeris' strategy is to patent early and often, including through a castle/moat approach that has led to numerous filings both at the platform and product levels. The addition of this new patent further strengthens our intellectual property position in the XeriSol platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products," said Paul R. Edick, Xeris' Chairman and CEO. The Xeris patent portfolio consists of 178 total patents globally, of which 33 are U.S. issued; 128 patent applications pending globally, of which 21 are pending in the U.S.; and 60 patents pertaining to its technology platform. Xeris' XeriSol patent portfolio includes patents and applications directed to this platform formulation technology, commercial and pipeline pharmaceutical product formulations, and therapeutic methods using such formulations to treat a variety of human diseases and disorders. All patents are owned by Xeris Biopharma subsidiaries.

07:03 EDT U.S. Silica announces price increases on Industrial and Specialty Products - U.S. Silica Holdings announced that its Industrial and Specialty Products segment will increase prices for most of its non-contracted products used primarily in glass, filtration, foundry, paints, coatings, elastomers, roofing, chemicals, recreation, building products and other applications. Price increases will range up to 20% depending on the product and grade and go into effect for shipments beginning June 1. These price increases are necessary to help offset significant and continuing cost increases in labor, transportation, materials and manufacturing costs.

07:02 EDT Alkermes submits Form 10 to SEC for planned separation of oncology business - Alkermes announced that it has submitted a confidential draft Form 10 registration statement to the United States SEC in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company. The company continues to expect to complete the separation in the second half of 2023. As announced in November 2022, Alkermes' Board of Directors unanimously approved the exploration of separating the company's neuroscience business and oncology business. The planned separation is part of a strategic process commenced by the Board to unlock shareholder value through a sharpened strategic focus, simplified capital allocation decision-making, and distinctive investment profiles for each business.

06:57 EDT Piedmont Lithium and Sayona Mining announce updated resources in Quebec - Piedmont Lithium's (PLL) joint venture partner, Sayona Mining (PLL), has released a definitive feasibility study for the jointly-owned North American Lithium project, and increased lithium mineral resources at its 60%-owned Moblan Lithium Project, both in the province of Quebec. Piedmont holds a 25% stake in NAL and an equity interest of approximately 14% in Sayona. The NAL DFS contemplates increased annual spodumene concentrate production averaging 190K metric tons per year over a 20-year mine life, with a target of 226K tpy in years one through four of steady state operations and approximately 186K tpy beginning in year five. The revised production targets resulted in an increase to the net present value for the NAL project compared to the prefeasibility study completed in 2022. The revised block model has resulted in a reduction in ore reserves and certain Indicated Resources have been reclassified as Inferred Resources. The study contemplates a mine life of 20 years, reduced from the prefeasibility study estimate of 27 years. Piedmont holds an offtake agreement with Sayona Quebec to purchase the greater of 113,000 tpy or 50% of the joint venture's spodumene concentrate production. Sayona Quebec is undertaking a prefeasibility study to explore downstream production at NAL and expects results in Q2. Separately, Sayona has announced a significant increase in mineral resources at its 60%-owned Moblan project in northern Quebec. Measured and Indicated Mineral Resources at Moblan now total 41.1 million metric tons @ 1.32% Li2O using a 0.55% Li2O cut-off grade.

06:52 EDT Endeavour Silver to proceed with underground mine, mill at Terronera Project - Endeavour Silver is pleased to announce the Board of Directors of the company has made the decision to proceed with the construction of an underground mine and mill at the Terronera Project in Jalisco state, Mexico. To date, the company made significant progress on development activities, with long-lead item procurement well advanced and a seasoned team of development personnel established on the ground. Additional activities include onsite delivery of mobile mining equipment, assembly of initial project infrastructure and advanced earthworks with commencement of underground mine access development.

06:46 EDT GSK to acquire Bellus Health for $14.75 per share - GSK plc (GSK) and Bellus Health (BLU) announced that they have entered into an agreement under which GSK will acquire Bellus, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough, or RCC, for $14.75 per share of common stock in cash representing an approximate total equity value of $2.0B, or GBP 1.6B. "The acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC," the companies stated. "The acquisition of BELLUS is highly synergistic with GSK's expertise in respiratory medicines and is further supported by GSK's leading R&D, manufacturing, and commercialisation capabilities. Following the anticipated regulatory approval and launch of camlipixant in 2026, the acquisition is expected to be accretive to adjusted EPS from 2027 and has the potential to deliver significant sales through 2031 and beyond," GSK said. "Under the terms of the agreement, the acquisition will be effected through a Plan of Arrangement pursuant to the Canada Business Corporations Act in which the shares of BELLUS outstanding will be acquired by the Company in consideration of US$14.75 per share in cash. Subject to customary conditions, including court approval, the approval of the acquisition by at least 66.67% of the votes cast at a meeting of BELLUS' shareholders and a majority of the votes cast by non-interested shareholders at such meeting, and approval by the appropriate regulatory agencies, the transaction is expected to close in the third quarter of 2023 or earlier. The per-share price represents a premium of approximately 103% to BELLUS' closing stock price on 17 April 2023 and a premium of approximately 101% to BELLUS' volume-weighted average price (VWAP) over the last 30 trading days. BELLUS' Board of Directors has unanimously recommended that BELLUS' shareholders vote in favour of the approval of the acquisition. GSK will account for the transaction as a business combination and expects it to be accretive to adjusted EPS in 2027, the expected first full year of camlipixant's sales. There is no change to GSK's full-year 2023 guidance or the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR at CER," GSK added.

06:38 EDT Ampio CEO issues letter to stockholders regarding operational focus - Ampio released the following letter to stockholders from its chairman, Kevin Buchi and CEO, Mike Martino. The company said, "On March 28, 2023, we filed our 2022 Annual Report on Form 10-K. In this letter we would like to elaborate on two key operational points which were included in that Annual Report. Firstly, we want to elaborate on progress with the development of what we have previously called, "AR-300." We gained a considerable amount of knowledge about osteoarthritis (OA) from the company's previous clinical and in vitro studies with Ampion. In January 2022, we began work on "AR-300," a series of synthetic formulations of what we believed to be the three active pharmaceutical ingredients (APIs) that were present at low levels in Ampion. Our development efforts in the first quarter 2023 have focused on rigorously testing different formulations of these APIs at an independent, well-respected research organization, using two validated, well-published rodent models of OA, which we will highlight here. The first model, called the medial meniscal tear (MMT) model, results in pathology that highly resembles the pathology that occurs with OA in humans, and is the most common preclinical model used by industry to identify potential therapies that may inhibit cartilage degeneration associated with OA. The second model, the mono-iodoacetate (MIA) model, measures the effects of potential therapies on the pain associated with progressive stages of OA, and is also the most common preclinical model used by industry to identify potential therapies to treat the pain associated with OA. To-date, we have shown cartilage protection in the MMT model with multiple combinations of the prospective APIs, with one formulation generating especially encouraging results. Additionally, in the MIA model, several alternative formulations have demonstrated immediate and early pain reduction in the inflammatory pain phase of the model. The combination of pain reduction and prevention of cartilage degeneration provides optimism that we have a drug candidate to treat OA of the knee (OAK). Of course, we will have to demonstrate these benefits in clinical trials acceptable to regulators and payers, but we are encouraged by these results. Additionally, we want to emphasize that these are results that were never observed with Ampion, nor with the original formulations of AR-300. These results show that we are now in possession of new and unique formulations, separate and distinct from both Ampion and AR-300, that demonstrate their own therapeutic potential. Because of that, we have already taken steps to protect this new intellectual property, worldwide. Based on this progress, we have focused our ongoing efforts toward optimizing two potential formulations to take forward into development. In the third quarter of 2023, we intend to select one of these optimized formulations to move towards clinical development. Given that these formulations are unique, proprietary, and are neither Ampion nor AR-300 (or derivatives thereof), we will now refer to development of these new formulations as OA-20X program. With the data from these additional studies, we will be in position later this year to seek scientific advice meetings with the FDA, UK, and EU regulatory authorities.Secondly, we want to elaborate on our progress in implementing a hybrid, virtual organizational model. From the outset, our intent was (and remains) to retain the organizational capabilities to govern a publicly traded company, comply with related reporting requirements, lead strategy development and program selection, and identify, retain, and manage third-party contractors with specific and proven expertise in the different, related activities required to develop a drug (e.g., drug candidate selection, formulation development, GMP manufacturing, preclinical development, clinical development, regulatory, etc.) on a just-in-time, as needed basis. We believe this model positions us to drive strategic development in the most expeditious and cost-effective way. We communicated, and began implementing, this organizational strategy at the end of 2022 with a planned reduction in force, which continued into the first quarter 2023. In addition, we entered into a sublease agreement effective March 1, 2023, whereby we have subleased the entire Ampio facility in Colorado. As a result of implementing this organizational strategy, Ampio now has five full-time employees, numerous engaged consultants with industry leading expertise in osteoarthritis (OA) drug development (as outlined above) and independent labs and contract manufacturing partners, all collaborating to further the development of the OA-20x program. We expect to remain a Colorado-based company for the foreseeable future and for the time being have retained our current mailing address. We estimate that this strategy will result in annualized cost savings of approximately $4.6 million, allowing us to focus our cash investment on OA-20x development for 2023 in addition to our ongoing governance and reporting obligations as a publicly traded company and other necessary expenses. Again, this update elaborates on just two points from our recently filed Annual Report, and we encourage you to read the full Annual Report in its entirety because it contains important information. We look forward to updating you following conclusion of the third quarter 2023."

06:33 EDT NexGen Energy, CRDN establish gravel supply company in Northwest Saskatchewan - NexGen Energy in partnership with the Clearwater River Dene Nation, or CRDN, announced the establishment of a 100% Indigenous owned and operated gravel supply company in Northwest Saskatchewan. Continuing to deliver on its industry-leading Impact Benefit Agreement with the CRDN signed in March 2022, NexGen purchased a $4.1M gravel crusher to provide aggregate material for its Rook I project and to supply the northern communities' aggregate material for road infrastructure requirements. The CRDN member-owned business will lease to own and operate the gravel crusher. The aggregate supply for Rook I has a capital expenditure representing an estimated $36M in value to the new CRDN-owned business in just the first three years of construction of the Project. This new company will immediately create 16 additional jobs for local community members.

06:27 EDT Parsons selected for Chester Bridge replacement project - Parsons's Critical Infrastructure segment has been selected by the Missouri Department of Transportation as a member of the design-build team for the Bi-State Chester Bridge Design-Build project over the Mississippi River between Perryville, MO and Chester, IL to replace the existing aging and outdated truss bridge. Parsons, as a subcontractor to Ames Construction, will serve as lead designer to provide a unique 4-span, 3-tower cable stay bridge design that will minimize risk to navigation traffic on the river.

06:03 EDT Bullfrog AI signs licensing agreement for oncology asset with university - BullFrog AI announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole. The exclusive license was signed on October 13, 2022. The world-wide, royalty-bearing license includes the rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications.

05:27 EDT Ericsson says on track to reach target EBITDA range of 15%-18% by 2024 - The company said, "We continue to see a choppy environment during 2023 with poor visibility. In Q2, we expect operators to remain cautious with capex investments and continue to adjust inventories. We expect this dynamic to largely be offset by growth from large roll-out projects which, as noted earlier, will be dilutive to gross margin in the short term. In the Enterprise segment, we remain confident of the long-term growth trajectory, and we expect the slower growth we saw in Q1, caused by the slower global economy, to continue in Q2. For Q2, we expect Group EBITA[2] margin to reach mid-single-digit level. We expect a gradual recovery in the second half of 2023, primarily as we expect the inventory adjustments to be completed and our cost reduction activities to start flowing through the P&L. Long-term, previous experience tells us that when operators are seeing underlying traffic growth, this leads to investments in networks in order to avoid deteriorating quality. Our strategy is paying off and we are excited about our position to capitalize on the full value of 5G. We are driving our transformation to a platform company with a focus on creating a stronger and more profitable Ericsson with a larger addressable market. With the expected recovery by 2024 of the Mobile Networks market, the turnaround of Cloud Software and Services, portfolio adjustments, enhanced R&D productivity, increased IPR revenues and cost reductions, we are on track to reaching the lower end of the long-term EBITA[2] target range of 15-18% by 2024."

05:18 EDT Elbit Systems awarded $102M contract by international customer - Elbit Systems announced that it was awarded a contract worth approximately $102M to supply artillery systems to an international customer. The contract will be performed over a period of eight years. Under the contract Elbit Systems will supply a battalion's worth of ATMOS 155mm/52 caliber truck-mounted howitzers systems. The ATMOS modular artillery system is a combat proven wheeled Howitzer solution, capable of firing all NATO-certified 155mm projectiles that has an effective range of over 40km with standard projectiles and offers extended range with Rocket-Assisted Projectiles, or RAP. The ATMOS is designed for rapid deployment and operation enabling provision of fire support for a broad range of missions.

05:12 EDT Elbit Systems awarded $100M follow-on contract by international customer - Elbit Systems announced that it was awarded a follow-on contract worth approximately $100M to convert commercial aircraft into Intelligence and Electronic Warfare, or EW, aircraft for an international customer. The contract will be performed over a period of three years. As part of the contract, Elbit Systems will equip the aircraft with advanced Intelligence Mission Suite and EW capabilities. This solution will provide a comprehensive operational picture of the arena generated by SIGINT and Electro-Optics VISINT sensors and systems as well as the capability to activate Electronic Counter Measures against a range of threats. The aircraft will also be equipped with Immune Satellite Navigation Systems, or ISNS, and an advanced self-protection solution.